Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience Ratios and Metrics

Market cap in millions USD. Fiscal year is September - August.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 1, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020
Market Capitalization	29	62	8	18	35	31
Market Cap Growth	135.50%	627.66%	-51.77%	-50.18%	13.53%	-42.60%
Enterprise Value	21	53	5	10	27	29
Last Close Price	1.64	3.91	1.05	2.96	6.22	10.38
PS Ratio	47.16	133.15	37.56	68.97	48.92	98.93
PB Ratio	2.93	8.07	3.17	2.31	2.71	12.55
P/TBV Ratio	3.92	8.22	3.29	2.36	2.74	13.95
EV/Sales Ratio	41.86	114.33	21.58	39.44	37.19	92.55
Debt / Equity Ratio	0.01	0.02	0.06	0.01	0.01	0.06
Asset Turnover	0.07	0.08	0.04	0.02	0.09	0.11
Inventory Turnover	-	-	-	2.11	2.39	0.81
Quick Ratio	28.15	6.10	5.99	32.79	78.90	7.20
Current Ratio	29.64	7.18	8.04	35.96	81.18	8.53
Return on Equity (ROE)	-114.83%	-112.36%	-130.18%	-71.35%	-73.16%	-166.85%
Return on Assets (ROA)	-67.50%	-59.56%	-73.59%	-39.21%	-44.17%	-94.23%
Return on Capital (ROIC)	-69.40%	-66.91%	-76.32%	-39.70%	-44.99%	-101.11%
Earnings Yield	-25.43%	-9.38%	-78.45%	-41.27%	-11.39%	-12.63%
FCF Yield	-22.83%	-8.09%	-69.63%	-27.98%	-11.28%	-8.41%
Buyback Yield / Dilution	-93.37%	-87.24%	-12.38%	-34.02%	-58.34%	-6.95%

Updated Jan 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q